DOPAMINE FIBER DETECTION BY [C-11] CFT AND PET IN A PRIMATE MODEL OF PARKINSONISM

被引:95
作者
HANTRAYE, P
BROWNELL, AL
ELMALEH, D
SPEALMAN, RD
WULLNER, U
BROWNELL, GL
MADRAS, BK
ISACSON, O
机构
[1] HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115
[2] MCLEAN HOSP,NEUROREGENERAT LAB,BELMONT,MA 02178
[3] MASSACHUSETTS GEN HOSP,DEPT NUCL RADIOL,BOSTON,MA 02114
[4] HARVARD UNIV,SCH MED,DEPT PSYCHIAT,BOSTON,MA 02115
[5] NEW ENGLAND REG PRIMATE RES CTR,DIV BEHAV BIOL,SOUTHBOROUGH,MA 01772
[6] CNRS,URA 1285,F-91406 ORSAY,FRANCE
关键词
POSITRON EMISSION TOMOGRAPHY; DOPAMINE UPTAKE INHIBITOR; C-11]-CFT; MPTP; DOPAMINE FIBER LOSS;
D O I
10.1097/00001756-199203000-00013
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
MONKEYS were treated on two regimens of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) injections to achieve dopamine fiber degeneration of differing severities. A rapid treatment regimen produced a severe parkinsonian syndrome, whereas an intermittent regimen did not cause locomotor symptoms to appear up to 25 weeks. High resolution PET scanning of dopamine nerve terminals revealed that the specific binding of the dopamine transporter [C-11]-WIN 35,428 ([C-11]-CFT) was diminished by 94% (caudate nucleus) and by 93% (putamen) in the symptomatic monkey. Decreases of 65 and 67% were detected in these regions in the non-symptomatic monkey. Post-mortem immunocytochemical evaluation of presumed dopamine fibers by tyrosine-hydroxylase showed similar reductions in the symptomatic animal.
引用
收藏
页码:265 / 268
页数:4
相关论文
共 18 条
  • [1] Agid Y, 1987, MOVEMENT DISORD, V1, P166
  • [2] INVIVO EVALUATION OF STRIATAL DOPAMINE REUPTAKE SITES USING C-11 NOMIFENSINE AND POSITRON EMISSION TOMOGRAPHY
    AQUILONIUS, SM
    BERGSTROM, K
    ECKERNAS, SA
    HARTVIG, P
    LEENDERS, KL
    LUNDQUIST, H
    ANTONI, G
    GEE, A
    RIMLAND, A
    UHLIN, J
    LANGSTROM, B
    [J]. ACTA NEUROLOGICA SCANDINAVICA, 1987, 76 (04): : 283 - 287
  • [3] BJORKLUND A, 1987, HDB PHYSL NERVOUS SY, P155
  • [4] BROWNELL GL, 1985, METABOLISM HUMAN BRA, P13
  • [5] CLARKE CE, 1988, N-S ARCH PHARMACOL, V338, P35
  • [6] MAPPING COCAINE BINDING-SITES IN HUMAN AND BABOON BRAIN INVIVO
    FOWLER, JS
    VOLKOW, ND
    WOLF, AP
    DEWEY, SL
    SCHLYER, DJ
    MACGREGOR, RR
    HITZEMANN, R
    LOGAN, J
    BENDRIEM, B
    GATLEY, SJ
    CHRISTMAN, D
    [J]. SYNAPSE, 1989, 4 (04) : 371 - 377
  • [7] SEVERE DEPLETION OF COCAINE RECOGNITION SITES ASSOCIATED WITH THE DOPAMINE TRANSPORTER IN PARKINSONS-DISEASED STRIATUM
    KAUFMAN, MJ
    MADRAS, BK
    [J]. SYNAPSE, 1991, 9 (01) : 43 - 49
  • [8] KILBOURN MR, 1989, NUCL MED BIOL, V16, P569
  • [9] BRAIN DOPAMINE METABOLISM IN PATIENTS WITH PARKINSONS-DISEASE MEASURED WITH POSITRON EMISSION TOMOGRAPHY
    LEENDERS, KL
    PALMER, AJ
    QUINN, N
    CLARK, JC
    FIRNAU, G
    GARNETT, ES
    NAHMIAS, C
    JONES, T
    MARSDEN, CD
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1986, 49 (08) : 853 - 860
  • [10] MADRAS BK, 1989, MOL PHARMACOL, V36, P518